Research Current study
Opening soonThe Hidden Readiness Gap
From AI Activity to Decision Advantage in Life Sciences
Help identify what enables life science organizations, including pharmaceutical, biotech, medical device and equipment, and life science tools companies, to turn AI activity into better decisions and reliable value.
- Time
- About 8 to 10 minutes
- Format
- 19 core questions, online
- Participation
- Voluntary and confidential
From AI activity to decision advantage
Many organizations can point to AI pilots and tools. Fewer can show that AI has changed a consequential decision. This study looks at the organizational conditions that make the difference.
Decision impact
Where AI has changed important decisions or ways of working, whether that impact is measured, and what most limits its value.
Data fit
Whether the data behind priority AI initiatives is documented, traceable and fit for its intended use, whether it is created internally or sourced externally.
Governance and accountability
How clearly organizations can define what AI is approved to do, who is accountable for the outcome and where responsibility would break down after an error.
Human oversight
When human judgment is built into AI-enabled workflows, and how organizations decide what AI can do independently and where people must review or decide.
Workforce and roles
How far roles, incentives and career paths have been updated for AI-enabled work.
External partner readiness
How ready the CROs, CDMOs, labs, data partners and technology providers that AI initiatives depend on are to support them.
Investment discipline
Whether investment approvals account for the full cost of making AI, data, lab and automation investments work.
Leadership blind spots
The AI risks senior leaders most often underestimate, and the challenges they are not yet discussing clearly enough.
For this survey, AI includes predictive analytics, machine learning, generative AI and AI-enabled automation.
Who should take part
Primary participants
Senior leaders at Vice President level or above in life science organizations, including pharmaceutical, biotech, medical device and equipment, and life science tools companies. Leaders with equivalent executive responsibility for strategy, portfolio, investment or operating decisions are also included.
Other perspectives
Anyone working in a life science or healthcare organization is welcome to take part, at any level and in any function. Their responses are analyzed separately from the primary group.
Your responses are confidential.
- We collect your name, company, role and email alongside your answers for research and study administration.
- Published findings will not identify you or your company without your permission.
- Sharing your name, company and job title is expected. Please do not include patient information, trade secrets or confidential details about your organization's products, plans or data.
- Participation does not subscribe you to marketing or authorize sales outreach. It does not require a newsletter subscription, a sales conversation or a LinkedIn connection.
- A Study Privacy Notice explaining how we use and protect your information will be available when the survey opens.
Questions about the study
For questions about the study, corrections to your responses or withdrawal, email info@talongroup.consulting.
Help build the evidence base
Your perspective helps show what separates AI activity from decision advantage across the life sciences.